Theranos (defunct) vs Enron Corporation (defunct)
Founding story, key facts and history — side by side.
Theranos (defunct)
Valued at $9 billion on technology that didn't exist. Elizabeth Holmes is in federal prison.
| Founded | 2003 |
| Founders | Elizabeth Holmes |
| HQ | Palo Alto, California |
| Symbol | Bankrupt |
VS
Enron Corporation (defunct)
America's seventh largest company. Named most innovative six years running. Entirely fictional.
| Founded | 1985 |
| Founders | Kenneth Lay |
| HQ | Houston, Texas |
| Symbol | Bankrupt |
The Story — Side by Side
2003
The Stanford dropout with a big idea
Elizabeth Holmes dropped out of Stanford University in 2003 at age 19, having completed one year of chemical engineering. She founded Theranos with her tuition refund money and a single idea: a blood testing device that could run hundreds of diagnostic tests from a single drop of blood taken from a finger prick. Holmes deepened her voice, adopted Steve Jobs's black turtleneck as her uniform, and began pitching. The pitch was extraordinarily effective.
2014
$9 billion, Walgreens, and a board of generals and secretaries of state
By 2014, Theranos had raised over $700 million in funding at a $9 billion valuation, making Holmes the youngest female self-made billionaire in history. Walgreens and Safeway had partnered with Theranos to offer blood tests in their stores. Theranos's board included former Secretaries of State Henry Kissinger and George Shultz, former Secretary of Defense James Mattis, and former Senators. None had scientific or medical expertise. None asked to see Theranos's data. The most credentialed board in Silicon Valley history was also the most incurious.
2015
John Carreyrou starts asking questions
Wall Street Journal reporter John Carreyrou began investigating Theranos in 2015 after a tip from a source. He discovered that Theranos's proprietary testing device — the Edison — could only run a handful of tests reliably. The company was secretly running most tests on conventional Siemens laboratory equipment while telling patients and investors it was using its own technology. Holmes's lawyers sent Carreyrou threatening letters. He published anyway. His book, "Bad Blood," became one of the most widely read business narratives of the decade.
2018
Indictment
Elizabeth Holmes and former Theranos president Ramesh "Sunny" Balwani were indicted on federal wire fraud charges in June 2018. The government alleged they had knowingly deceived investors, doctors, and patients. Patients had made medical decisions — including decisions about cancer treatment — based on inaccurate Theranos test results. The company had dissolved in 2018 after its laboratory certification was revoked.
2022
Guilty. Eleven years in federal prison.
Elizabeth Holmes was convicted of four counts of criminal fraud in January 2022 and sentenced to 11 years in federal prison. She appealed multiple times and attempted to delay her surrender date, exhausting every available legal avenue. She began serving her sentence in May 2023. Ramesh Balwani was convicted on all 12 counts against him and sentenced to nearly 13 years. The case became the defining narrative of Silicon Valley's "fake it till you make it" culture — and its catastrophic limits when the product is a medical device and the patients are real people receiving incorrect diagnoses.
1985
A gas pipeline company with ambitions
Enron was formed in 1985 through the merger of Houston Natural Gas and InterNorth. Kenneth Lay became CEO and, with the help of Jeffrey Skilling, transformed Enron from a regulated utility into an energy trading company. Skilling's idea was radical: treat natural gas not as a physical commodity but as a financial instrument, and trade it like stocks and bonds. For a time, it worked brilliantly. Enron's stock rose over 1,000% in the 1990s.
1996
Six consecutive years as America's most innovative company
Fortune Magazine named Enron America's "Most Innovative Company" for six consecutive years from 1996 to 2001. Enron was celebrated as a model of the new economy — asset-light, trading-focused, staffed by brilliant people compensated with enormous bonuses. The company expanded from gas into electricity, water, broadband, and eventually weather derivatives. Every consultant who visited left impressed. Almost none of them looked at the actual cash flows.
1999
Mark-to-market accounting and the illusion of profit
Enron used an accounting technique called "mark-to-market" that allowed it to book the estimated future profits of long-term contracts immediately, as current revenue. When Enron signed a 20-year contract to supply broadband, it could book the estimated profit from all 20 years in the current quarter — regardless of whether the broadband network existed or the contract was ever fulfilled. This created the appearance of massive, growing profits while actual cash flows were negative.
2001
The analyst who asked a simple question
In March 2001, Bethany McLean of Fortune Magazine published an article asking a simple question: "Is Enron Overpriced?" She noted that Enron's financial statements were incomprehensible and that the company could not explain precisely how it made money. Enron CEO Jeffrey Skilling called McLean "unethical." Within months, the financial structure McLean had questioned began to collapse. Enron's CFO Andrew Fastow had created hundreds of off-balance-sheet entities to hide over $1 billion in debt from investors and regulators.
2001
The largest bankruptcy in U.S. history
Enron filed for bankruptcy on December 2, 2001 — the largest corporate bankruptcy in U.S. history at the time, with $63 billion in assets. Twenty thousand employees lost their jobs and their pension savings, which had been invested in Enron stock that became worthless. Kenneth Lay died of a heart attack before sentencing. Jeffrey Skilling was convicted of fraud and conspiracy and sentenced to 24 years in prison, later reduced to 14 years. The scandal led directly to the Sarbanes-Oxley Act — the most significant overhaul of corporate accounting rules in U.S. history. Arthur Andersen, one of the world's largest accounting firms and Enron's auditor, was also destroyed.
Tools & Platforms
For Investors
The market doesn't care about your feelings.
But your broker's fees do.
But your broker's fees do.
Most people have a brokerage account. Fewer understand what it really costs them — in spreads, in fees, in missed instruments. Malta-regulated, direct market access, 600,000+ instruments.
Exante
Malta MFSA · 50 exchanges
Tickmill
Forex from 0.0 pips
Vantage
Multi-asset trading
Polymarket
Prediction markets
For Entrepreneurs
Opening a US company costs $300.
Most people think it's complicated. It isn't.
Most people think it's complicated. It isn't.
Most founders spend weeks on formation, banking and payments. The ones who move fast know which tools to use before they start. A US LLC, a real business account, and a way to pay people — in that order.
Mercury
Business finance · 300K+ founders
Doola
US LLC formation · YC backed
Melio
B2B payments
Xero 95% OFF
Accounting · 6 months
For C-Suite
Your competitor pays $200 less per month for EOR.
You're still on a spreadsheet.
You're still on a spreadsheet.
BVNK hired 20% of its workforce through Deel. The smartest operators aren't managing payroll complexity — they're outsourcing it. EOR in 150+ countries, multi-currency accounts, workforce payments at $200 less per month than competitors.
Deel
EOR · 150+ countries
Payoneer
$399/mo EOR · Save $200
Wise Business
40+ currencies · No hidden fees
Gusto
US payroll & benefits
PLUS
2.0%
back in crypto · on every spend
€3.99 / month
or €39.90/year (€3.32/month)
Zero trading fees up to $20K/month
2.0% back in crypto on card spend
0% foreign exchange fees
EUR Cash Yield up to 1.35% p.a.
CRO Yield up to 2.00% p.a.
Virtual Visa card · Flexible cancel
PRO
3.0%
back in crypto · on every spend
€24.99 / month
or €249.90/year (€20.82/month)
Zero trading fees up to $50K/month
3.0% back in crypto on card spend
0% foreign exchange fees
EUR Cash Yield up to 1.70% p.a.
CRO Yield up to 2.50% p.a.
Airport lounge access (Priority Pass)
PRIVATE
4–6%
back in crypto · on every spend
CRO Lockup from €45,000
8.5% yield · 12-month staking · €450K tier at 9.5%
Zero trading fees · Unlimited volume
4.0%–6.0% back in crypto
0% foreign exchange fees
EUR Cash Yield up to 1.80% p.a.
Extra 1% p.a. on Earn allocations in CRO
VIP events · Exclusive experiences
8.5% CRO lockup rewards